NASH cirrhosis is the end stage of non-alcoholic steatohepatitis (NASH), where the scar tissue and regenerative nodules resulting from the inflammation and fibrosis of NASH has replaced healthy liver tissue, preventing the liver from functioning normally and potentially causing liver failure and death.
The NAVIGATE Study Phase 2b/3 clinical trial specifically targets NASH cirrhosis, seeking to prevent the development of varices and possibly other more serious complications of NASH cirrhosis.
NASH cirrhosis tends to worsen over time. Scar tissue and the formation of nodules progressively displace healthy liver tissue, ultimately causing liver failure.
NASH cirrhosis is fast becoming the leading cause of liver transplants in the U.S.
There are a variety of information resources available to NASH cirrhosis patients and their families. These include: